Company: BSX
Filing Date: 2025-02-18
Form Type: 10-K
Source: 0000885725-25-000011
Chunk: 183

Company: BOSTON SCIENTIFIC CORP
Filing Date: 2025-02-18
Form: 10-K
Item: Item 8
Chunk 183
---
ed AverageGrant-Date Fair ValueBalance as of December 31, 20219,745 $37 Granted3,854 45 Vested(1)(3,482)36 Forfeited(680)44 Balance as of December 31, 20229,438 $41 Granted3,958 49 Vested(1)(3,624)39 Forfeited(485)44 Balance as of December 31, 20239,287 $45 Granted3,322 66 Vested(1)(3,717)43 Forfeited(349)50 Balance as of December 31, 20248,544 $54 (1) The number of shares vested includes shares withheld on behalf of employees to satisfy statutory tax withholding requirements.The total vesting date fair value of shares that vested was approximately $248 million in 2024, $171 million in 2023 and $150 million in 2022.

110

Market-based RSU AwardsDuring 2024, 2023 and 2022 we granted market-based RSU awards to certain members of our senior management team. The number of shares ultimately issued to the recipient is based on the total stockholder return (TSR) of our common stock as compared to the TSR of the common stock of the other companies in the S&P 500 Health Care Index over a three-year period. The number of RSUs ultimately granted under this program range from 0 percent to 200 percent of the target number awarded to the participant as determined by achievement of the TSR criteria of the program. In addition, in general, award recipients must remain employed by us throughout the three-year period to attain the full amount of the market-based RSUs that satisfied the market performance criteria.The aggregate fair value of these awards as determined based on Monte Carlo simulations as of the respective grant dates, and the related assumptions used in the valuations, are as follows: 202420232022AwardsAwardsAwardsFair value (in millions)$16 $13 $12 Stock price on date of grant$64.99 $47.28 $44.19 Measurement period (in years)2.92.92.9Risk-free rate4.23 %4.31 %1.71 %We recognize the expense on these awards in our consolidated statements of operations on a straight-line basis over the three-year measurement period.Organic Net Sales Growth and